miR-373-3p promotes aerobic glycolysis in colon cancer cells by targeting MFN2

• miR-373-3p promotes aerobic glycolysis and proliferation in colon cancer cells by directly targeting and inhibiting MFN2 expression. • In vivo, miR-373-3p enhances tumor growth and lactate production in a nude mouse model, while miR-373-3p antagomir suppresses tumor growth. • In human colon cancer tissues, miR-373-3p is upregulated and MFN2 mRNA is downregulated, with an inverse correlation. • Targeting miR-373-3p represents a potential therapeutic strategy for colon cancer treatment.